Monlunabant — Safety, Research, Risks & Legal Status

Not medical advice. Monlunabant is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	INV-202, MRI-1891, S-MRI-1891
Category	GLP-1 / Metabolic
Drug class	Peripherally-restricted CB1 cannabinoid receptor inverse agonist (beta-arrestin-2-biased)
Developer	Novo Nordisk A/S (via acquisition of Inversago Pharmaceuticals, August 2023, ~$1B)
Development stage	Phase 2 completed for obesity and diabetic kidney disease; Phase 2b/3 registrational program planned mid-2026
Phase 2a weight loss (10 mg, 16 wk)	7.1 kg vs. 0.7 kg placebo (N=243; statistically significant)
Kidney disease outcome	Phase 2 primary endpoint missed; development status under review
Key safety concern	Dose-dependent neuropsychiatric AEs (anxiety, irritability, sleep disturbance) despite peripheral-restriction design intent
US legal status	Investigational drug only; no FDA-approved indication as of mid-2026. Not cleared for human use outside of clinical trials. Classified as an unapproved drug under US law. Novo Nordisk holds the development portfolio following acquisition of Inversago Pharmaceuticals (2023).

What is Monlunabant?

Monlunabant is a peripherally-restricted, once-daily oral small molecule that acts as an inverse agonist at the CB1 cannabinoid receptor. It was designed to selectively target CB1 receptors in metabolically active peripheral tissues - adipose tissue, gastrointestinal tract, kidneys, liver, pancreas, skeletal muscle, and lungs - while minimizing CNS penetration, which has historically been the source of serious psychiatric adverse effects with this drug class. It is currently in Phase 2 clinical development for obesity and metabolic syndrome under Novo Nordisk, which acquired it from Inversago Pharmaceuticals in August 2023 for approximately $1 billion.

How it works

Monlunabant binds the CB1 cannabinoid receptor and acts as an inverse agonist - reducing constitutive receptor activity below baseline rather than merely blocking agonist binding. It is described as beta-arrestin-2-biased, a functional selectivity property intended to favor peripheral tissue distribution and limit CNS accumulation. CB1 receptors in adipose and hepatic tissue modulate lipogenesis, energy expenditure, and insulin sensitivity; antagonism or inverse agonism at these sites is hypothesized to reduce fat mass and improve cardiometabolic parameters. Despite the peripheral-restriction design intent, human trial data indicate the compound does accumulate in brain to a clinically meaningful degree, producing dose-dependent neuropsychiatric signals.

Background & history

The CB1 blockade strategy for obesity was pioneered by Sanofi's rimonabant, a CNS-penetrant CB1 inverse agonist withdrawn from European markets in 2008-2009 following recognition of a doubled risk of psychiatric disorders including depression and suicidality. This withdrawal effectively halted the class. Inversago Pharmaceuticals was founded on the premise that peripheral restriction of CB1 blockade could separate the metabolic benefit from central psychiatric toxicity. Their lead compound, INV-202/monlunabant, entered clinical trials and was acquired mid-program by Novo Nordisk in August 2023 for ~$1 billion, signaling high commercial interest in the mechanism. Phase 2a obesity results published in The Lancet Diabetes and Endocrinology (2025) showed statistically significant weight loss at the 10 mg dose. A separate Phase 2 trial in diabetic kidney disease missed its primary endpoint.

What the research says

Two completed Phase 2 trials with available human data. The Phase 2a obesity/metabolic syndrome trial (NCT05891834, N=243, 16 weeks) found that monlunabant 10 mg once daily produced 7.1 kg mean weight loss versus 0.7 kg for placebo, a statistically significant difference. Higher doses (20 mg, 50 mg) showed no meaningful incremental efficacy benefit. Full results were published in The Lancet Diabetes and Endocrinology (2025); open-label extension data appeared in Diabetes, Obesity and Metabolism (2026). A Phase 2 trial in diabetic kidney disease (NCT05514548) missed its primary endpoint; the status of further kidney disease development is under review. A Phase 2b/3 registrational program for obesity was planned for initiation in mid-2026. No Phase 3 data are yet available. The diabetic kidney disease failure and persistent neuropsychiatric signals represent the key unresolved clinical questions for the program.

Reported effects

Statistically significant weight reduction in Phase 2a obesity trial at 10 mg dose (7.1 kg vs. 0.7 kg placebo at 16 weeks)
No meaningful incremental weight loss observed at higher doses (20 mg, 50 mg) versus 10 mg in Phase 2a
Intended modulation of CB1 receptor activity in adipose, hepatic, gastrointestinal, renal, and muscle tissue
No demonstrated efficacy in diabetic kidney disease (primary endpoint missed in Phase 2 trial)
Dose-dependent neuropsychiatric adverse effects including anxiety, irritability, and sleep disturbance reported in trials
Dose-dependent gastrointestinal adverse effects, predominantly mild-to-moderate in severity

Dosing & administration (informational)

In the completed Phase 2a trial, doses of 10 mg, 20 mg, and 50 mg once daily were evaluated over 16 weeks. The 10 mg dose demonstrated the best efficacy-to-tolerability profile; higher doses showed no additional weight loss benefit and greater neuropsychiatric adverse effect burden. These are investigational trial doses from a single completed study and are cited here for informational context only. They are not a dosing protocol. Monlunabant is not approved for any use, and no dosing guidance outside a clinical trial should be inferred from this entry. Consult a licensed clinician for any questions about treatment.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Dose-dependent mild-to-moderate anxiety, irritability, and sleep disturbance observed in clinical trials despite peripheral-restriction design
Brain accumulation confirmed at clinically relevant levels, undermining the peripheral-selectivity rationale
Gastrointestinal adverse effects were the most common class of AE in trials; predominantly mild-to-moderate and dose-dependent
No serious psychiatric adverse events or suicidal ideation were reported in completed trials to date, but the dataset is limited to Phase 2
Class-level concern: predecessor CB1 blocker rimonabant was withdrawn in 2008-2009 due to doubled psychiatric disorder risk including depression and suicidality; long-term psychiatric safety of monlunabant remains unestablished
Diabetic kidney disease Phase 2 trial missed primary endpoint; renal effects in humans remain poorly characterized
Long-term safety profile is entirely unknown; no Phase 3 or long-duration controlled data available as of mid-2026

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
a
r
e
p
u
b
l
i
c
l
y
d
o
c
u
m
e
n
t
e
d
a
t
t
h
i
s
p
i
p
e
l
i
n
e
s
t
a
g
e
.
A
s
a
C
B
1
i
n
v
e
r
s
e
a
g
o
n
i
s
t
,
t
h
e
o
r
e
t
i
c
a
l
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
i
n
t
e
r
a
c
t
i
o
n
s
a
r
e
a
n
t
i
c
i
p
a
t
e
d
w
i
t
h
c
a
n
n
a
b
i
n
o
i
d
s
(
i
n
c
l
u
d
i
n
g
T
H
C
-
c
o
n
t
a
i
n
i
n
g
p
r
o
d
u
c
t
s
)
a
n
d
p
o
t
e
n
t
i
a
l
l
y
w
i
t
h
o
t
h
e
r
C
N
S
-
a
c
t
i
v
e
a
g
e
n
t
s
g
i
v
e
n
t
h
e
o
b
s
e
r
v
e
d
b
r
a
i
n
p
e
n
e
t
r
a
t
i
o
n
.
M
e
t
a
b
o
l
i
c
p
a
t
h
w
a
y
d
a
t
a
h
a
v
e
n
o
t
b
e
e
n
p
u
b
l
i
s
h
e
d
f
o
r
t
h
e
g
e
n
e
r
a
l
l
i
t
e
r
a
t
u
r
e
.
N
o
i
n
t
e
r
a
c
t
i
o
n
s
c
a
n
b
e
c
h
a
r
a
c
t
e
r
i
z
e
d
w
i
t
h
c
o
n
f
i
d
e
n
c
e
b
a
s
e
d
o
n
a
v
a
i
l
a
b
l
e
p
u
b
l
i
c
d
a
t
a
.

Who should avoid it

Cannabis or THC-containing products (direct pharmacodynamic antagonism at CB1)
Any use outside of a registered clinical trial - compound is investigational only
Self-administration of any substance sold as monlunabant outside clinical channels (identity and purity unverifiable)
Use by individuals with personal or family history of psychiatric disorders given class-level neuropsychiatric risk signal
Assuming peripheral-restriction marketing language eliminates CNS psychiatric risk - human data show brain accumulation and neuropsychiatric AEs do occur

How it is commonly combined

No stacking data exist. Monlunabant has not been studied in combination with GLP-1 receptor agonists, other anti-obesity pharmacotherapy, or other metabolic agents. The compound is investigational and not approved for any use; combination use outside a clinical trial is not evaluable from available evidence.

Legal & regulatory. Investigational drug only; no FDA-approved indication as of mid-2026. Not cleared for human use outside of clinical trials. Classified as an unapproved drug under US law. Novo Nordisk holds the development portfolio following acquisition of Inversago Pharmaceuticals (2023).

Quality & harm reduction

Safer, legal alternative we recommend

Liver Let Live. For liver and metabolic support, our Liver Support formula is a legal supplement option covering a similar goal.

See our recommended pick

Find Monlunabant →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

How does monlunabant differ from rimonabant, the CB1 blocker withdrawn in 2009?

Rimonabant was a CNS-penetrant CB1 inverse agonist; it freely crossed the blood-brain barrier and produced a doubled rate of psychiatric disorders including depression and suicidal ideation, leading to its withdrawal. Monlunabant was designed with structural modifications intended to restrict it to peripheral tissues. However, Phase 2 human trial data show the compound does accumulate in the brain at pharmacologically meaningful levels, and dose-dependent neuropsychiatric adverse effects - anxiety, irritability, and sleep disturbance - have been observed. Whether monlunabant's psychiatric risk profile is materially better than rimonabant's will require Phase 3 data and longer-term surveillance.

What was the efficacy result in the Phase 2a obesity trial?

In a 16-week Phase 2a trial (NCT05891834, N=243), monlunabant 10 mg once daily produced a mean weight loss of 7.1 kg compared to 0.7 kg in the placebo group, a statistically significant difference. Higher doses (20 mg and 50 mg) did not produce meaningfully greater weight loss and were associated with more adverse effects. These are single-trial results from a relatively short, Phase 2 study; Phase 3 confirmation has not yet occurred.

Did monlunabant work for diabetic kidney disease?

No. A separate Phase 2 trial (NCT05514548) evaluating monlunabant in diabetic kidney disease missed its primary endpoint. The status of further development for that indication is under review by Novo Nordisk. The kidney disease program appears to be in jeopardy based on currently available public disclosures.

What is the correct dose to use?

Monlunabant is an unapproved investigational drug and there is no approved or recommended dose for any indication. The doses evaluated in trials (10 mg, 20 mg, 50 mg once daily) are cited in the research literature for informational context only. This entry does not provide dosing guidance, and no use outside a registered clinical trial is appropriate. Please consult a licensed clinician for any questions about treatment options.

Is monlunabant available to buy?

No legitimate commercial supply exists. Monlunabant is an investigational compound held within Novo Nordisk's clinical development program. Any product sold online or through research chemical vendors as monlunabant has unverifiable identity, purity, and dosing - and would not be legal for human consumption in the United States.

When might monlunabant be FDA-approved?

As of mid-2026, the compound remains in Phase 2. A Phase 2b/3 registrational program was planned for initiation in mid-2026, but no timeline to potential approval has been publicly confirmed. Regulatory approval would require successful Phase 3 trial completion, NDA submission, and FDA review - a process that typically takes several additional years from Phase 3 initiation, and is not guaranteed given the neuropsychiatric safety signals and the kidney disease Phase 2 failure.

References & further reading

PubMed: monlunabant obesity metabolic syndrome phase 2 Lancet Diabetes Endocrinology 2025
PubMed: monlunabant open-label extension obesity Diabetes Obesity Metabolism 2026
ClinicalTrials.gov: NCT05891834 (monlunabant obesity metabolic syndrome Phase 2a)
ClinicalTrials.gov: NCT05514548 (monlunabant diabetic kidney disease Phase 2)
PubMed: CB1 cannabinoid receptor inverse agonist peripheral restriction obesity mechanism review